David Agus, co-founder of Navigenics, and neurosurgeon Keith Black share how Alzheimer's might be predicted and cured with new understanding of how the disease interacts with the human brain.
Dr. David B. Agus
David Agus is one of the world’s top cancer doctors and a pioneer in new technologies for personalized health care. A professor at USC, with appointments in both the Keck School of Medicine and the Viterbi School of Engineering, he also heads the university’s Westside Cancer Center and the Center for Applied Molecular Medicine. He has cofounded several businesses, including the genetic testing company Navigenics and Oncology.com. He is also a cofounder of Applied Proteomics, which aims to tap the tremendous wealth of information contained in the body’s proteome—the complete set of all proteins circulating in the bloodstream—for earlier diagnosis of disease. Agus is a CBS News contributor and author of the number one New York Times best seller The End of Illness. His new book, A Short Guide to a Long Life, will be published in January 2014.
Keith Black is an American neurosurgeon specialising in the treatment of brain tumors and a prolific campaigner for funding of cancer treatment. He is chairman of the neurosurgery department and
director of the Maxine Dunitz Neurosurgical Institute at Cedars-Sinai Medical Center in Los Angeles, California.